Calculator Guides
GOLD COPD Assessment in 2026: Diagnosis, Spirometric Grade and Exacerbation Group
Editorial record
This source-linked educational article has been updated through AI-assisted evidence checks and editorial review. Verify information against current guidance and local protocols before applying it to patient care.
Citation methodology"GOLD 2" and "group E" are not alternative names for the same stage. The first describes airflow limitation; the second belongs to a symptom and exacerbation framework. Recording both, with the guideline year and treatment context, prevents a misleading one-number summary.
Establish the Entry Criteria
Do not begin by assigning a grade to an unexplained low FEV1. COPD assessment requires an appropriate clinical history and quality-assured spirometry. GOLD uses post-bronchodilator FEV1/FVC below 0.70 to demonstrate obstruction in the relevant clinical context. Obstruction is not specific to COPD.
The GOLD Science Committee spirometry recommendations explain why pre- and post-bronchodilator results are not interchangeable. They also discuss repeating testing when results are near the diagnostic threshold. The 2026 GOLD report advises confirmation on a separate occasion when a single post-bronchodilator ratio lies between 0.60 and 0.80, because biological variation can change classification.
A ratio of 0.68 in an asymptomatic person is therefore not sufficient to announce COPD without considering test quality, repeat measurements and clinical context. Equally, a preserved ratio with reduced FEV1 should not be forced into a COPD grade.
Keep the Measurements Separate
FEV1 and FVC are volumes, commonly reported in litres. Their ratio is dimensionless. FEV1 % predicted compares measured FEV1 with the laboratory's reference value; it is not the ratio multiplied by 100.
Once COPD is established, the GOLD airflow-limitation grades are: 1 at FEV1 at least 80% predicted; 2 from 50% to below 80%; 3 from 30% to below 50%; and 4 below 30%. These categories do not encode an individual's symptom burden or treatment requirement. See the diagnostic assessment in the current GOLD resources.
Add Symptoms and Event History
For the initial A/B/E assessment in GOLD 2026, no moderate or severe exacerbations in the preceding year places the patient on the A/B branch. Lower symptom burden corresponds to A; greater burden corresponds to B. GOLD uses symptom-assessment thresholds of mMRC 2 or more or Chronic Airways Assessment Test (CAAT, formerly CAT) 10 or more to identify greater burden. Obtain the assessment using the official instrument; the questionnaire and scale wording are not reproduced here.
At least one moderate or severe exacerbation in the preceding year places the patient in E, irrespective of symptom burden. This differs from older versions that allowed a single nonhospitalised moderate event in A or B. The 2026 key-changes summary explicitly explains the changed significance of one event and the separation of initial from follow-up treatment.
Check the history rather than counting every respiratory prescription. Document dates, clinical descriptions, treatment and emergency or hospital contacts, including which severity definition was used. Historical utilisation-based labels are not interchangeable with physiological severity assessment: the GOLD Science Committee's 2026 discussion states that GOLD no longer recommends classifying exacerbation severity by site of care. The classification of a previous event does not replace objective clinical assessment of a patient who is acutely deteriorating now.
Fictional Worked Assessment
A fictional adult has compatible symptoms and exposure history, with established COPD after appropriate diagnostic assessment. Quality-assured post-bronchodilator values are:
- FEV1: 1.20 L.
- FVC: 2.40 L.
- Laboratory predicted FEV1: 2.00 L.
- Officially assessed mMRC grade: 1.
- One confirmed moderate COPD exacerbation in the preceding 12 months.
The ratio is 1.20 / 2.40 = 0.50. Separately, FEV1 is **1.20 / 2.00 * 100 = 60% predicted, giving airflow-limitation grade 2. If this is an initial assessment, the event history places the person in group E under GOLD 2026**, despite the lower recorded dyspnoea grade.
An appropriate summary is "COPD, GOLD airflow-limitation grade 2; initial assessment group E using GOLD 2026", accompanied by the underlying observations. It is not "60% obstruction" or "stage 2, so no exacerbation risk".
What the Classification Cannot Decide
If the person is already receiving maintenance treatment, review symptoms, exacerbations, adherence, inhaler technique and competing disease through the follow-up framework. Do not select a new treatment solely by rerunning initial grouping. Nor can a spirometric grade establish oxygen eligibility, explain all breathlessness or predict a fixed survival time.
Version-check a calculator before using its A/B/E output: an implementation based on an earlier year's event thresholds can disagree with this article without any arithmetic error. This article does not establish that the site's calculator has been updated.
Learning Question
In the worked case, does mMRC 1 make the person group A?
No. Confirmed exacerbation history takes precedence in the initial 2026 grouping. The 60% predicted FEV1 supplies a separate airflow grade; it does not cancel the event history.
AI-assisted clinician education. Primary sources checked on 17 October 2026. Apply local diagnostic and treatment pathways; this article is not a prescribing algorithm.
Related calculators
- GOLD COPD Staging Calculator - Pulmonology